TipRanks (Tue, 13-Jan 11:10 AM ET)
Charles River Labs outlines 2026 outlook and acquisitions
TipRanks (Tue, 13-Jan 8:28 AM ET)
TipRanks (Tue, 13-Jan 4:00 AM ET)
Charles River Laboratories Provides Business Updates
Business Wire (Mon, 12-Jan 4:30 PM ET)
Notable healthcare headlines for the week: AbbVie, UnitedHealth, and Novo Nordisk in focus
Seeking Alpha News (Sun, 11-Jan 9:05 AM ET)
Charles River Labs Announces CEO Succession and Leadership Changes
TipRanks (Fri, 9-Jan 4:51 PM ET)
TipRanks (Fri, 9-Jan 5:15 AM ET)
Analysts Are Bullish on Top Healthcare Stocks: ANI Pharmaceuticals (ANIP), Charles River Labs (CRL)
TipRanks (Fri, 9-Jan 4:40 AM ET)
TipRanks (Thu, 8-Jan 10:46 AM ET)
Charles River Laboratories appoints Birgit Girshick as CEO following James Foster's retirement
Seeking Alpha News (Thu, 8-Jan 8:30 AM ET)
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Charles River Laboratories International trades on the NYSE stock market under the symbol CRL.
As of January 13, 2026, CRL stock price climbed to $218.99 with 995,550 million shares trading.
CRL has a beta of 0.19, meaning it tends to be less sensitive to market movements. CRL has a correlation of 0.00 to the broad based SPY ETF.
CRL has a market cap of $11.20 billion. This is considered a Large Cap stock.
Last quarter Charles River Laboratories International reported $1 billion in Revenue and $2.43 earnings per share. This beat revenue expectation by $17 million and exceeded earnings estimates by $.10.
In the last 3 years, CRL traded as high as $275.00 and as low as $91.86.
The top ETF exchange traded funds that CRL belongs to (by Net Assets): VTI, VOO, VB, RSP, IVV.
CRL has underperformed the market in the last year with a return of +17.7%, while SPY returned +20.8%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in CRL shares. However, CRL has outperformed the market in the last 3 month and 2 week periods, returning +31.1% and +7.8%, while SPY returned +6.5% and +0.9%, respectively. This indicates CRL has been having a stronger performance recently.
CRL support price is $213.81 and resistance is $223.83 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CRL shares will trade within this expected range on the day.